Literature DB >> 24623041

Belief elicitation to populate health economic models of medical diagnostic devices in development.

Wieke Haakma1, Lotte M G Steuten, Laura Bojke, Maarten J IJzerman.   

Abstract

BACKGROUND AND
OBJECTIVE: Bayesian methods can be used to elicit experts' beliefs about the clinical value of healthcare technologies. This study investigates a belief-elicitation method for estimating diagnostic performance in an early stage of development of photoacoustic mammography (PAM) imaging versus magnetic resonance imaging (MRI) for detecting breast cancer. RESEARCH
DESIGN: Eighteen experienced radiologists ranked tumor characteristics regarding their importance to detect malignancies. With reference to MRI, radiologists estimated the true positives and negatives of PAM using the variable interval method. An overall probability density function was determined using linear opinion pooling, weighted for individual experts' experience. RESULT: The most important tumor characteristics are mass margins and mass shape. Respondents considered MRI the better technology to visualize these characteristics. Belief elicitation confirmed this by providing an overall sensitivity of PAM ranging from 58.9 to 85.1% (mode 75.6%) and specificity ranging from 52.2 to 77.6% (mode 66.5%).
CONCLUSION: Belief elicitation allowed estimates to be obtained for the expected diagnostic performance of PAM, although radiologists expressed difficulties in doing so. Heterogeneity within and between experts reflects this uncertainty and the infancy of PAM. Further clinical trials are required to validate the extent to which this belief-elicitation method is predictive for observed test performance.

Entities:  

Mesh:

Year:  2014        PMID: 24623041     DOI: 10.1007/s40258-014-0092-y

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


  7 in total

Review 1.  Methods to elicit probability distributions from experts: a systematic review of reported practice in health technology assessment.

Authors:  Bogdan Grigore; Jaime Peters; Christopher Hyde; Ken Stein
Journal:  Pharmacoeconomics       Date:  2013-11       Impact factor: 4.981

Review 2.  Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study.

Authors:  Laura Bojke; Marta Soares; Karl Claxton; Abigail Colson; Aimée Fox; Christopher Jackson; Dina Jankovic; Alec Morton; Linda Sharples; Andrea Taylor
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

Review 3.  A review and classification of approaches for dealing with uncertainty in multi-criteria decision analysis for healthcare decisions.

Authors:  Henk Broekhuizen; Catharina G M Groothuis-Oudshoorn; Janine A van Til; J Marjan Hummel; Maarten J IJzerman
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

4.  The premarket assessment of the cost-effectiveness of a predictive technology "Straticyte™" for the early detection of oral cancer: a decision analytic model.

Authors:  S Khoudigian-Sinani; G Blackhouse; M Levine; L Thabane; D O'Reilly
Journal:  Health Econ Rev       Date:  2017-10-02

Review 5.  Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature.

Authors:  Maarten J IJzerman; Hendrik Koffijberg; Elisabeth Fenwick; Murray Krahn
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

Review 6.  Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses.

Authors:  Marta O Soares; Linda Sharples; Alec Morton; Karl Claxton; Laura Bojke
Journal:  Value Health       Date:  2018-04-25       Impact factor: 5.725

Review 7.  A Scoping Review of Different Methods of Assessing the Impact of New Medical Technologies at Early Stages of Development.

Authors:  Zahra Goudarzi; Shekoufeh Nikfar; Abbas Kebriaeezadeh; Reza Yousefi Zenouz; Akbar Abdollahi Asl; Nader Tavakoli
Journal:  Med J Islam Repub Iran       Date:  2021-10-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.